About Us



Quality Certifications

2022

Obtained three ISO certifications under the Integrated Management System:
– ISO 9001:2015
– ISO 15189:2012
– ISO 17025:2017
The Group gets affected issuer status uplifted, Bursa Securities waives need for Group to submit
regularisation plan.
Acquired 51% of Aquahealth Sdn Bhd to pioneer renal care via Rinani Renal Berhad.

2021

Established centralised facility housing a new genomics laboratory, a biosafety level 2 cell laboratory, and the company’s headquarters.
Partnered with Pharmaniaga Lifesciences Sdn Bhd on the distribution of COVID-19 vaccines around Malaysia.

2020

Diversification into CAR T-cell immunotherapy for cancers.

2019

Divested MPath Sdn Bhd to unlock the value of the investment into pathology.

2016

Acquired remaining 50% of Clinipath Pathology via MPath Sdn Bhd.

2012

Diversified into clinical pathology services by acquiring 50% of Clinipath Pathology via MPath Sdn Bhd.

2011

Launched Dtect® genetic screening tests (14 different genetic screening profiles today).

2010

Listed on the ACE Market of Bursa Malaysia Securities Berhad.

2009

Completed the world’s largest genome assembly of the oil palm genome.

2005

Commenced contract genomics research services for international customers including Brigham & Women’s Hospital (the teaching affiliate of Harvard Medical School), Novartis, AstraZeneca, Pure Circle, April Pulp & Paper, etc.

2004

Incorporated Malaysian Genomics Resource Centre Berhad.

Certifications

Malaysian Genomics Resource Centre Berhad has successfully obtained three ISO certifications under the Integrated Management System.

Associations